« Back to Record
Citation APA

Asselah, T., Alami, N. N., Moreno, C., Pol, S., Karatapanis, S., Gschwantler, M., Horsmans, Y., Elefsiniotis, I., Larrey, D., Ferrari, C., Rizzetto, M., Orlandini, A., Calleja, J. L. U. J., Bruno, S., Schnell, G., Qaqish, R. R., Redman, R., Pilot-Matias, T., Kopecky-Bromberg, S., Yu, Y., & Mobashery, N. (2019). Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Science Reports, 2(3), e92. doi:10.1002/hsr2.92


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/307490

Asselah, T., Alami, N. N., Moreno, C., Pol, S., Karatapanis, S., Gschwantler, M., Horsmans, Y., Elefsiniotis, I., Larrey, D., Ferrari, C., Rizzetto, M., Orlandini, A., Calleja, J. L. U. J., Bruno, S., Schnell, G., Qaqish, R. R., Redman, R., Pilot-Matias, T., Kopecky-Bromberg, S., Yu, Y., & Mobashery, N. (2019). Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Science Reports, 2(3), e92. doi:10.1002/hsr2.92